Introducing Mi~Scan®
The new standard for breast tissue composition analysis
(Coming Soon - The Mi~Scan® device is currently undergoing its first clinical trial/s and is expected to be available for order from October (in Europe) with shipments following receipt of European regulatory approval, in early 2025)
Mi~Scan® uses safe, non-ionising radio waves to quickly measure and then analyse breast tissue properties.
The device does not require breast compression and can be used as frequently as required, in both diagnostic and primary care settings.
Know your breast density.
The ratio of fibro-glandular tissue to other tissues in your breast can significantly impact the ability of a standard Mammogram to detect cancer.
While the amount of fibro-glandular tissue typically reduces with age (particularly post-menopause), women of all ages can have “dense” breasts.
The good news is that other techniques are available that have higher sensitivity and specificity in “dense” breasts.
Density cannot be determined by the look or feel of a breast, and even interpretation from a Mammogram can be subjective.
The initial Mi~Scan® product quickly measures breast density, producing a density score that allows a woman to be referred for the most effective imaging technique for her tissue type first time.
Our ultimate goal is for the device to be used to assess breast cancer risk for all women, quickly, safely, comfortably and as frequently as required.
— Adrian Waller (Micrima CEO)